Literature DB >> 19236911

Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.

Ziwen Liu1, Linlin Zhong, Paulette A Krishack, Sarah Robbins, Julia X Cao, Yupei Zhao, Stephen Chung, Deliang Cao.   

Abstract

Aldo-keto reductase family 1 member B10 (AKR1B10) is overexpressed in human hepatocellular carcinoma, lung squamous carcinoma, and lung adenocarcinoma in smokers. Our recent studies have showed that AKR1B10 plays a critical role in the growth and proliferation of cancer cells by detoxifying reactive carbonyls and regulating fatty acid biosynthesis. However, little is known about the regulatory mechanisms of AKR1B10 expression. In this study, we determined the structure of AKR1B10 gene and characterized its promoter. The results demonstrated that AKR1B10 consists of 10 exons and 9 introns, stretching approximately 13.8 kb. A 5'-RACE study determined the transcriptional start site of AKR1B10 at 320 bp upstream of the ATG translational start codon. A TATA-like (TAATAA) and a CAAT box are present from -145 to -140 bp and -193 to -190 bp upstream of the transcriptional start site, respectively. Motif analysis recognized multiple putative oncogenic and tumor suppressor protein binding sites in the AKR1B10 promoter, including c-Ets-1, C/EBP, AP-1, and p53, but osmolytic response elements were not found. A -4091 bp of the 5'-flanking fragment of the AKR1B10 gene was capable of driving GFP and luciferase reporter gene expression in HepG2 cells derived from human hepatocellular carcinoma; progressive 5'-deletions revealed that a -255 bp fragment possesses full promoter activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236911      PMCID: PMC2668737          DOI: 10.1016/j.gene.2009.02.007

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  32 in total

Review 1.  Primer on medical genomics. Part VII: The evolving concept of the gene.

Authors:  Eric D Wieben
Journal:  Mayo Clin Proc       Date:  2003-05       Impact factor: 7.616

Review 2.  Lipid rafts and signal transduction.

Authors:  K Simons; D Toomre
Journal:  Nat Rev Mol Cell Biol       Date:  2000-10       Impact factor: 94.444

3.  Characterization of the human aldose reductase gene promoter.

Authors:  K Wang; K M Bohren; K H Gabbay
Journal:  J Biol Chem       Date:  1993-07-25       Impact factor: 5.157

4.  Overexpression of aldose reductase in liver cancers may contribute to drug resistance.

Authors:  K W Lee; B C Ko; Z Jiang; D Cao; S S Chung
Journal:  Anticancer Drugs       Date:  2001-02       Impact factor: 2.248

5.  Organization and chromosomal localization of the human platelet-derived endothelial cell growth factor gene.

Authors:  K Hagiwara; G Stenman; H Honda; P Sahlin; A Andersson; K Miyazono; C H Heldin; F Ishikawa; F Takaku
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

6.  Membrane raft microdomains mediate front-rear polarity in migrating cells.

Authors:  S Mañes; E Mira; C Gómez-Moutón; R A Lacalle; P Keller; J P Labrador; C Martínez-A
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

7.  Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma.

Authors:  Gunhild Trøen; Vigdis Nygaard; Tor-Kristian Jenssen; Ida Münster Ikonomou; Anne Tierens; Estella Matutes; Alicja Gruszka-Westwood; Daniel Catovsky; Ola Myklebost; Grete Lauritzsen; Eivind Hovig; Jan Delabie
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

8.  Metabolic labelling of membrane microdomains/rafts in Jurkat cells indicates the presence of glycerophospholipids implicated in signal transduction by the CD3 T-cell receptor.

Authors:  Alexandre K Rouquette-Jazdanian; Claudette Pelassy; Jean-Philippe Breittmayer; Jean-Louis Cousin; Claude Aussel
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

9.  The aldo-keto reductase superfamily homepage.

Authors:  David Hyndman; David R Bauman; Vladi V Heredia; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2003-02-01       Impact factor: 5.192

10.  Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism.

Authors:  Bernat Crosas; David J Hyndman; Oriol Gallego; Sílvia Martras; Xavier Parés; T Geoffrey Flynn; Jaume Farrés
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

View more
  13 in total

1.  AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.

Authors:  Linlin Zhong; Honglin Shen; Chenfei Huang; Hongwu Jing; Deliang Cao
Journal:  Toxicol Appl Pharmacol       Date:  2011-05-26       Impact factor: 4.219

2.  The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.

Authors:  Rajash Pallai; Henry Simpkins; Jianli Chen; Hemant K Parekh
Journal:  Gene       Date:  2010-03-23       Impact factor: 3.688

3.  AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.

Authors:  Nicholas Shaw; Bingmei Yang; Ann Millward; Andrew Demaine; Andrea Hodgkinson
Journal:  Cell Stress Chaperones       Date:  2013-08-23       Impact factor: 3.667

4.  Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.

Authors:  Shunsuke Sato; Takuya Genda; Katsuharu Hirano; Hironori Tsuzura; Yutaka Narita; Yoshio Kanemitsu; Tetsu Kikuchi; Katsuyori Iijima; Ryo Wada; Takafumi Ichida
Journal:  Liver Int       Date:  2012-06-11       Impact factor: 5.828

5.  Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.

Authors:  Yeon Tae Chung; Kristina A Matkowskyj; Haonan Li; Han Bai; Wanying Zhang; Ming-Sound Tsao; Jie Liao; Guang-Yu Yang
Journal:  Mod Pathol       Date:  2012-01-06       Impact factor: 7.842

6.  Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.

Authors:  Toshiyuki Matsunaga; Yasuhiro Wada; Satoshi Endo; Midori Soda; Ossama El-Kabbani; Akira Hara
Journal:  Front Pharmacol       Date:  2012-01-31       Impact factor: 5.810

7.  Pro-oncogene Pokemon promotes breast cancer progression by upregulating survivin expression.

Authors:  Xuyu Zu; Jun Ma; Hongxia Liu; Feng Liu; Chunyan Tan; Lingling Yu; Jue Wang; Zhenhua Xie; Deliang Cao; Yuyang Jiang
Journal:  Breast Cancer Res       Date:  2011-03-10       Impact factor: 6.466

8.  Propofol suppresses cell proliferation in gastric cancer cells through NRF2-mediated polyol pathway.

Authors:  Yajun Cao; Long Fan; Linkai Li; Jiexian Zhou
Journal:  Clin Exp Pharmacol Physiol       Date:  2021-11-09       Impact factor: 2.963

Review 9.  The Role of AKR1B10 in Physiology and Pathophysiology.

Authors:  Satoshi Endo; Toshiyuki Matsunaga; Toru Nishinaka
Journal:  Metabolites       Date:  2021-05-21

10.  High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.

Authors:  Sang Yun Ha; Dae Hyun Song; Jae Jun Lee; Hyun Woo Lee; Soo Youn Cho; Cheol-Keun Park
Journal:  Gut Liver       Date:  2014-10-07       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.